Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sulfosalicylic. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.93 |
| ▸ | HPGD | P15428 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | PHLPP2 | Q6ZVD8 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfosalicylic SCHEMBL3297465 | 1.00 | ALDH1A1 (0.93) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL8769448 | 0.98 | ALDH1A1 (0.96) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL8592874 | 0.98 | ALDH1A1 (0.89) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL29034690 | 0.98 | ALDH1A1 (0.89) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL6717073 | 0.98 | ALDH1A1 (0.96) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL34766 | 0.98 | ALDH1A1 (0.96) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL29364125 | 0.98 | ALDH1A1 (0.96) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL25356542 | 0.96 | ALDH1A1 (0.93) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL818713 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10KDM4EHPGDMEN1 | |
| Sulfosalicylic SCHEMBL8030761 | 0.96 | ALDH1A1 (0.93) | ALDH1A1HSD17B10KDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0570861-B1 | Laser apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1997-07-30 | — | — | EP | claimed |
| US-5381429-A | Deuterium | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1995-01-10 | — | — | US | claimed |
| EP-0570861-A1 | Laser apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-11-24 | — | — | EP | claimed |
| CN-109137007-B | Environmentally friendly nickel electroplating compositions and methods | 罗门哈斯电子材料有限责任公司 | 2020-07-07 | — | — | CN | disclosed |
| EP-3431634-A1 | ENVIRONMENTALLY FRIENDLY NICKEL ELECTROPLATING COMPOSITIONS AND METHODS | Rohm and Haas Electronic Materials LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180363157-A1 | ENVIRONMENTALLY FRIENDLY NICKEL ELECTROPLATING COMPOSITIONS AND METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2018-12-20 | — | — | US | disclosed |
| US-9963473-B2 | Stabilized form of tetrofosmin and its use | ROTOP PHARMAKA GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20160355532-A1 | STABILIZED FORM OF TETROFOSMIN AND ITS USE | ROTOP PHARMAKA GMBH (DE) | 2016-12-08 | — | — | US | disclosed |
| EP-3022215-B1 | STABILIZED FORM OF TETROFOSMIN AND ITS USE | ROTOP PHARMAKA GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-3022215-A1 | STABILIZED FORM OF TETROFOSMIN AND ITS USE | Rotop Pharmaka GmbH (DE) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015114002-A1 | STABILIZED FORM OF TETROFOSMIN AND ITS USE | ROTOP PHARMAKA GMBH (DE) | 2015-08-06 | — | — | WO | disclosed |
| US-20030091945-A1 | Silver halide color photographic material and method of reducing magenta stain | FUJI PHOTO FILM CO., LTD. | 2003-05-15 | — | — | US | disclosed |
| US-20030064329-A1 | Silver halide color reversal photographic material | FUJI PHOTO FILM CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| EP-1241522-A1 | Processing method for silver halide color photographic material | Fuji Photo Film Co., Ltd. (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-20020025497-A1 | Silver halide color photographic light-sensitive material and color image formation method using the same | FUJIFILM CORPORATION (JP) | 2002-02-28 | — | — | US | disclosed |
| CN-1062856-C | Process for preparing isocyanates | MONSANTO CO (US) | 2001-03-07 | — | — | CN | disclosed |
| EP-0570861-B1 | Laser apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1997-07-30 | — | — | EP | disclosed |
| CN-1143952-A | Process for preparing isocyanates | MONSANTO CO (US) | 1997-02-26 | — | — | CN | disclosed |
| US-5381429-A | Deuterium | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0570861-A1 | Laser apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355532-A1 | STABILIZED FORM OF TETROFOSMIN AND ITS USE | KTN1, TNNI3, TK1 | ALDH1A1 4753/4885HSD17B10 4835/4885KDM4E 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.